Transduction of recombinases for inducible gene targeting
CA 2396149 A1 · Owner: Artemis Pharmaceuticals Gmbh · Inventors: Schwenk, Frieder
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides the use of a fusion protein comprising a sitespecific DNA recombinase domain and a protein transduction domain for preparing an agent for inducing target gene alteration in a living organism or in cultured cells, suitable fusion proteins and a method for theproduction of said fusion proteins.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 5, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 5, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 5, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.